Corcept Therapeutics (NASDAQ:CORT): Q4 Revenue of $87.9M (+31.6% Y/Y) in-line.
Cash and investments of $315.3M
https://seekingalpha.com/news/3536595-corcept-therapeutics-reports-preliminary-q4-resultsThursday, January 30, 2020
Vertex up 3% after hours on Q4 beat, strong Trikafta launch
Vertex Pharmaceuticals (NASDAQ:VRTX) Q4 results:
Revenues: $1,413.3M (+62.4%); product sales: $1,413.3M (+62.8%).
Key product sales: Kalydeco: $236M (-8.9%); Orkambi: $270 (-14.3%); Symdeko/Symkevi: $332M (+12.9%); Trikafta: $420M.
Net income: $583.2M (-61.8%); non-GAAP net income: $444.3M (+31.9%); EPS: $2.23 (-62.6%); non-GAAP EPS: $1.70 (+30.8%).
2020 guidance: Product sales: $5.1B – 5.3B from $3.70B – 3.75B.
Shares up 3% after hours.
https://seekingalpha.com/news/3536513-vertex-up-3-after-hours-on-q4-beat-strong-trikafta-launch
Revenues: $1,413.3M (+62.4%); product sales: $1,413.3M (+62.8%).
Key product sales: Kalydeco: $236M (-8.9%); Orkambi: $270 (-14.3%); Symdeko/Symkevi: $332M (+12.9%); Trikafta: $420M.
Net income: $583.2M (-61.8%); non-GAAP net income: $444.3M (+31.9%); EPS: $2.23 (-62.6%); non-GAAP EPS: $1.70 (+30.8%).
2020 guidance: Product sales: $5.1B – 5.3B from $3.70B – 3.75B.
Shares up 3% after hours.
https://seekingalpha.com/news/3536513-vertex-up-3-after-hours-on-q4-beat-strong-trikafta-launch
Edwards Lifesciences EPS misses by $0.03, beats on revenue
Edwards Lifesciences (NYSE:EW): Q4 Non-GAAP EPS of $1.46 misses by $0.03; GAAP EPS of $1.32 misses by $0.09.
Revenue of $1.17B (+19.7% Y/Y) beats by $20M.
https://seekingalpha.com/news/3536578-edwards-lifesciences-eps-misses-0_03-beats-on-revenueAmgen EPS beats by $0.23, beats on revenue
Revenue of $6.2B (-0.5% Y/Y) beats by $160M.
https://seekingalpha.com/news/3536532-amgen-eps-beats-0_23-beats-on-revenueCoronavirus to have little impact on U.S. economy – Kudlow
The fast-spreading coronavirus, which has killed 170 people in China and infected six in the United States, should have little impact on the U.S. economy, President Donald Trump’s chief economic adviser said on Thursday.
“We see no material impact on our economy,” Larry Kudlow, director of
the National Economic Council Director, told Fox Business Network.
Kudlow said the Trump administration had taken a look at the outbreak of SARS, or Severe Acute Respiratory Syndrome, in the early-2000s and found the economic impact on the United States had been negligible. SARS was first reported in Asia and spread to more than two dozen countries.
“There was no material impact,” he said, adding, “This may or may not be worse.”
Cases of coronavirus globally surpassed 8,100 on Thursday, outstripping the total number of infections in the SARS epidemic of 2003.
The coronavirus crisis is forecast to sharply dent China’s economy, the world’s second-largest.
Kudlow said the United States stood ready to help, but said Beijing should not expect relief from U.S. trade tariffs.
“These are separate matters,” he said. “This is completely separate from issues of trade or related matters.”
https://www.marketscreener.com/news/Coronavirus-to-have-little-impact-on-U-S-economy-Trump-adviser–29916197/
Kudlow said the Trump administration had taken a look at the outbreak of SARS, or Severe Acute Respiratory Syndrome, in the early-2000s and found the economic impact on the United States had been negligible. SARS was first reported in Asia and spread to more than two dozen countries.
“There was no material impact,” he said, adding, “This may or may not be worse.”
Cases of coronavirus globally surpassed 8,100 on Thursday, outstripping the total number of infections in the SARS epidemic of 2003.
The coronavirus crisis is forecast to sharply dent China’s economy, the world’s second-largest.
Kudlow said the United States stood ready to help, but said Beijing should not expect relief from U.S. trade tariffs.
“These are separate matters,” he said. “This is completely separate from issues of trade or related matters.”
Nymox Provides Update on Current Corporate Activities and Milestones
Nymox Pharmaceutical Corporation (NYMX)
is pleased to provide a current January 2020 update on several
important corporate activities and achievements since the last update in
October 2019.
The
Company recently received the necessary information regarding the
formatting and content of its upcoming regulatory filings for its
Fexapotide Triflutate (FT) first in class injectable drug to treat the
symptoms of prostate enlargement (BPH) in men. The Company is proceeding
to integrate safety data from its four Phase I and Phase II BPH
clinical trials as well as the safety data from Prostate Cancer Study
NX03-0040 into the final dataset (that also includes 4 Phase 3 trials)
that will be part of the New Drug Application (NDA) submission. The
filings seeking approvals in the US and in Europe are now targeted for
the first half of 2020 in both jurisdictions. At this point, the Company
does not have any barriers to report and does not expect any delays.
Nymox
is further pleased to report that another peer review publication (as
anticipated in the Company’s October 21, 2019 Press Release) was
recently accepted and published in Research and Reports in Urology. This
publication discusses the selective cellular ablation capabilities of
Fexapotide Triflutate to induce apoptosis (natural cell death) in
prostate glandular cells which are a major part of the prostate
enlargement which defines benign prostatic hyperplasia. Selective
pharmaco-ablation is achieved while leaving the nerve cells and urethra
and other nearby tissues (all crucial for normal sexual function)
unaffected. In fact, the Company has previously reported a statistically
significant improvement in sexual function reported by men treated with
FT for BPH in its U.S. Phase III long-term follow up studies.
A
fourth new and important peer review article is expected to appear in
the near term. Further information will be provided when the new article
appears.
Dr
Paul Averback, CEO commented, “We are very pleased to provide these
positive substantiated updates to shareholders today. Now, after many
months of intensive work with our regulatory advisors and experts, we
are confident that we have the needed clarity concerning the optimal
formatting and content protocols being undertaken. The Company is
currently highly focused on expeditiously completing the final legs of
its regulatory pre-filing responsibilities.”
The
new peer review article reported in January 2020 and published in
Research and Reports in Urology provided detailed documentation of the
selective pharmco-ablation mechanism of action of FT, demonstrating the
highly selective reduction of prostate cells which comprises one of the
most important underlying reasons for the highly superior safety and
efficacy of Fexapotide.
https://finance.yahoo.com/news/nymox-provides-current-corporate-activities-143010396.html
Walgreens Primary Care Partner VillageMD Gobbles More Doctor Practices
VillageMd, which has a partnership with Walgreens in Houston, bought Summit Medical Group Arizona .
VillageMd and Walgreens photo
Fast-growing VillageMd said it is buying
an Arizona primary care practice for an undisclosed sum as the privately
held venture expands into new markets across the U.S.
Chicago-based VillageMD,
which includes Walgreens Boots Alliance as an investor and a partner in
the Houston area, said Thursday it has agreed to acquire Summit Medical
Group of Arizona, which includes nearly 50 medical providers that
include primary care physicians, nurse practitioners and physician
assistants. Another 185 staff members will work at the clinics that will
be “rebranded as Village Medical,” VillageMD said.The VillageMD acquisition comes as physicians and primary care practices generally find safety in numbers when it comes to landing contracts with health insurance companies that pay them and developing state-of-the-art care coordination. VillageMD is among the well-capitalized fast growing startups buying doctor practices along with bigger players like health insurer UnitedHealth Group’s Optum unit and Humana’s Partners in Primary Care. And the biggest buyer of doctor practices remains hospitals and big hospital systems that are also on a buying binge.
These smaller practices are attracted to bigger players given the cost of implementing health information systems and the latest technology.
“After two years of building a high-quality multi-specialty practice to benefit the residents of the Valley, we believe that VillageMD’s high-touch and effective clinical model, coupled with its technology platform, docOS, as well as their human capital resources, will help us provide world-class care to patients,” Summit Medical Group Arizona chief physician executive Dr. Kent Johnson said. “We are pleased to be part of such an innovative organization.”
By partnering with VillageMD, Walgreens said it is focusing on “providing adult patients in the Houston community with a transformative primary care experience.” The 2,500-square-foot clinics are being located next to Walgreens stores in the Houston area and be called “Village Medical at Walgreens.”
https://www.forbes.com/sites/brucejapsen/2020/01/30/walgreens-primary-care-partner-villagemd-gobbling-more-doctor-practices/#19c2f0b297c7
Subscribe to:
Posts (Atom)